• Home
  • NEW DAY MEDICINE
  • 7 (69) 2024
  • 37 -7 (69) 2024 - Mullabaeva G.U., Xakimov A.A. - TYPE OF PROSTHESIS AND THE ROLE OF DRUG TREATMENT AFTER PROSTHETIC SURGERY FOR MITRAL AND AORTIC VALVE DEFECTS

37 -7 (69) 2024 - Mullabaeva G.U., Xakimov A.A. - TYPE OF PROSTHESIS AND THE ROLE OF DRUG TREATMENT AFTER PROSTHETIC SURGERY FOR MITRAL AND AORTIC VALVE DEFECTS

TYPE OF PROSTHESIS AND THE ROLE OF DRUG TREATMENT AFTER PROSTHETIC SURGERY FOR MITRAL AND AORTIC VALVE DEFECTS

Mullabaeva G.U. - Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent

Xakimov A.A. - Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent

Fozilov X.G. - Republican Specialized Scientific and Practical Medical Center of Cardiology Tashkent

Resume

The review article discusses the problem of managing patients with heart defects and heart failure. the results of multicenter studies are discussed

Keywords: aortic stenosis, aortic valve insufficiency, mitral stenosis, mitral valve insufficiency, epidemiology, pathogenesis.

First page

213

Last page

219

For citation:Mullabaeva G.U., Xakimov A.A., Fozilov X.G. - TYPE OF PROSTHESIS AND THE ROLE OF DRUG TREATMENT AFTER PROSTHETIC SURGERY FOR MITRAL AND AORTIC VALVE DEFECTS//New Day in Medicine 7(69)2024 213-219 https://newdayworldmedicine.com/en/new_day_medicine/7-69-2024

List of References

  1. Lung B., Baron G., Butchart E.G. et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. //Eur Heart J 2003; 24: 1231—1243.
  2. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Даниелян М.О. От имени рабочей группы ОССН. Первые результаты национального эпидемиологического исследования — эпидемиологическое обследование больных ХСН в реальной практике (по обращаемости) — ЭПОХА-О-ХСН. //Сердечная недостаточность 2003; 4-3:116-120.
  3. ACC/ACH 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Developed in Collaboration With the Society of Cardiovascular Anestheologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. //J Am Coll Cardiol 2006;48:3:598-675.
  4. Эрдес Ш.Ф., Фоломеева О.М. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. //Научно-практ ревматол 2007;4:429.
  5. McMurray J., McDonagh T., Morrison C.E. et al. Trends in hospitalization for the heart failure in Scotland 1980—1990. //EurHeart J. 1993;14(9):1158-62.
  6. 2017 ESC/EACTS guidelines for the management of valvular heart disease 6. 2017; P-114.
  7. Vakamudi S, Jellis C, Mick S, Wu Y, Gillinov AM, Mihaljevic T, Cosgrove DM, Svensson L, Cho L. Sex differences in the etiology of surgical mitral valve disease. //Circulation 2018;138:17491751.
  8. Yu M, Georges A, Tucker NR, Kyryachenko S, Toomer K, Schott JJ, Delling FN, Fernandez-Friera L, Solis J, Ellinor PT, Levine RA, Slaugenhaupt SA, Hagege AA, Dina C, Jeunemaitre X, Milan DJ, Norris RA, Bouatia-Naji N. Genome-wide association study-driven gene-set analyses, genetic, and functional follow-up suggest GLIS1 as a susceptibility gene for mitral valve prolapse. //Circ Genom Precis Med 2019;12:e002497.
  9. Mantovani F, Clavel MA, Michelena HI, Suri RM, Schaff HV, Enriquez-Sarano M. Comprehensive imaging in women with organic mitral regurgitation: implications for clinical outcome. //JACC Cardiovasc Imaging 2016;9:388-396.
  10. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, Griffin BP, Desai MY. Outcomes of patients with mediastinal radiation-associated mitral valve disease undergoing cardiac surgery. //Circulation 2019;140:1288-1290.
  11. Mantovani F, Clavel MA, Michelena HI, Suri RM, Schaff HV, Enriquez-Sarano M. Comprehensive imaging in women with organic mitral regurgitation: implications for clinical outcome. //JACC Cardiovasc Imaging 2016; 9:388-396.
  12. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. //J Am Coll Cardiol 2015;65:1231-1248.
  13. Bertrand PB, Schwammenthal E, Levine RA, Vandervoort PM. Exercise dynamics in secondary mitral regurgitation: pathophysiology and therapeutic implications. //Circulation 2017;135:297-314.
  14. Deferm S, Bertrand PB, Verbrugge FH, Verhaert D, Rega F, Thomas JD, Vandervoort PM. Atrial functional mitral regurgitation: JACC Review Topic of the Week. //J Am Coll Cardiol 2019;73:2465-2476.
  15. Carità P, Coppola G, Novo G, et al. Aortic stenosis: insights on pathogenesis and clinical implications. //J Geriatr Cardiol. 2016;13(6):489-98. doi:10.11909/j.issn.1671-5411.2016.06.001.
  16. Capoulade R, Chan KL, Yeang C, et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. //J Am Coll Cardiol. 2015;66(11):1236-46. doi:10.1016/j. jacc.2015.07.020.
  17. Teo KK, Corsi DJ, Tam JW, et al. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. //Can J Cardiol. 2011;27(6):800-8. doi:10.1016/j.cjca.2011.03.012.
  18. Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. //Circulation. 2015;132:67790. doi:10.1161/CIRCULATIONAHA.115.016757.
  19. Karas’kov A. M., Nazarov V. M., Zheleznev S. I. i dr. Disfunkcii iskusstvennyh klapanov serdca. //Novosibirsk: Akademicheskoe izdatel’stvo Geo; 2008. [In Russ].
  20. Shihverdiev N. N., Hubulava G. G., Marchenko S. P. Diagnostika i lechenie oslozhnenij u bol’nyh s iskusstvennymi klapanami serdca. /Moskow: Foliant; 2006. [In Russ].

    file

    download